Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Frequency of homozygous deletion at p16/CDKN2 in primary human tumours


Many tumour types have been reported to have deletion of 9p21 (rets 1-6). A candidate target suppressor gene, p16 (p16INK4a/MTS-1/CDKN2), was recently identified within the commonly deleted region in tumour cell lines7,8. An increasing and sometimes conflicting body of data has accumulated regarding the frequency of homozygous deletion and the importance of p16 in primary tumours. We tested 545 primary tumours by microsatellite analysis with existing and newly cloned markers around the p16 locus. We have now found that small homozygous deletions represent the predominant mechanism of inactivation at 9p21 in bladder tumours and are present in other tumour types, including breast and prostate cancer. Moreover, fine mapping of these deletions implicates a 170 kb minimal region that includes p16 and excludes p15.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Diaz, M.O. et al. Deletions of interferon genes in acute lymphoblastic leukemia. N. Engl. J. Med. 332, 77–82 (1990).

    Article  Google Scholar 

  2. 2

    Fountain, J.W. et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. natn. Acad. Sci. U.S.A. 89, 10557–10561 (1992).

    CAS  Article  Google Scholar 

  3. 3

    James, C.D. et al. Chromosome 9 deletion mapping reveals interferon a and interferon β-1 gene deletions in human glial tumors. Cancer Res. 51, 1684–1688 (1991).

    CAS  PubMed  Google Scholar 

  4. 4

    Olopade, O.I. et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 53, 2410–2415 (1993).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5

    Cairns, P., Tokino, K., Eby, Y. & Sidransky, D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res. 54, 1422–1424 (1994).

    CAS  PubMed  Google Scholar 

  6. 6

    van der Riet, P. et al. Frequent loss of chromosome 9p21 -22 early in head and neck cancer progression. Cancer Res. 54, 1156–1158 (1994).

    CAS  PubMed  Google Scholar 

  7. 7

    Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436–440 (1994).

    CAS  Article  Google Scholar 

  8. 8

    Nobori, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753–756 (1994).

    CAS  Article  Google Scholar 

  9. 9

    Knudson, A.G., Jr., Hethcote, H.W. & Brown, B.W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. natn. Acad. Sci. U.S.A. 72, 5116–5120 (1975).

    Article  Google Scholar 

  10. 10

    Hussussian, C.J. et al. Germline p16 mutations in familial melanoma. Nature Genet. 8, 15–21 (1994).

    CAS  Article  Google Scholar 

  11. 11

    Mori, T. et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) in esophageal squamous cell carcinoma. Cancer Res. 54, 3396–3397 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12

    Caldas, C. et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8, 27–32 (1994).

    CAS  Article  Google Scholar 

  13. 13

    Hayashi, N., Sugimoto, Y., Tsuchiya, E., Ogawa, M. & Nakamura, Y. Somatic mutations of the MTS1 (multiple tumor suppressor) CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. biophys. Res. Commun. 202, 1426–1430 (1994).

    CAS  Article  Google Scholar 

  14. 14

    Kamb, A. et al. Analysis of the p16 gene (CDKA/2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8, 23–26 (1994).

    CAS  Article  Google Scholar 

  15. 15

    Xu, L. et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 54, 5269–5272 (1994).

    Google Scholar 

  16. 16

    Zhou, X. et al. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9, 3737–3747 (1994).

    CAS  PubMed  Google Scholar 

  17. 17

    Okamoto, A. et al. Mutations in the p16(INK4)/MTS1/CDKN2,p15(INK4B)/ MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 55, 1448–1451 (1995).

    CAS  PubMed  Google Scholar 

  18. 18

    Cairns, P. et al. Rates of p16(MTS1) mutations in primarytumors with 9p loss. Science 265, 415–416 (1994).

    CAS  Article  Google Scholar 

  19. 19

    Xu, L., et al. Mutational analysis of CDKN2 (MTS1/P16INK4) in human breast carcinomas. Cancer Res. 54, 5262–5264 (1994).

    CAS  PubMed  Google Scholar 

  20. 20

    Jen, J. et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353–6358 (1994).

    CAS  PubMed  Google Scholar 

  21. 21

    Middleton-Price, H., Spurr, N., Hall, A. & Malcolm, S. N-ras-like sequences on chromosomes 9,6 and 22 with a polymorphism at the chromosome 9 locus. Ann. hum. Genet. b, 189–195 (1988).

    CAS  Article  Google Scholar 

  22. 22

    Sauter, G. et al. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. Int. J. Cancer 64, 99–103 (1995).

    CAS  Article  Google Scholar 

  23. 23

    Kamb, A., Liu, Q., Harshman, K. & Tavtigian, S. Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 265, 416–417 (1994).

    CAS  Article  Google Scholar 

  24. 24

    Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995).

    CAS  Article  Google Scholar 

  25. 25

    Roy, N. et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80, 167–178 (1995).

    CAS  Article  Google Scholar 

  26. 26

    Cairns, P., Shaw, M.E. & Knowles, M.A. Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome 9. Oncogene 8, 1083–1085 (1993).

    CAS  PubMed  Google Scholar 

  27. 27

    Merlo, A., et al. CpG island methylation is associated with transcriptional silencing of the tumour suppressor CDKN2/p16 in human cancers. Nature Med. 1, 686–692 (1995).

    CAS  Article  Google Scholar 

  28. 28

    Weaver-Feldhaus, J. et al. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc. natn. Acad. Sci. U.S.A. 91, 7563–7567 (1994).

    CAS  Article  Google Scholar 

  29. 29

    Zhang, J., Meltzer, P., Jenkins, R., Guan, X.Y., Trent, J. Application of chromosome microdissection probes for elucidation of BCR-ABL fusion and variant Philadelphia chromosome translocations in chronic myelogenous leukemia. Blood 81, (12), 3365–3371 (1993).

    Google Scholar 

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cairns, P., Polascik, T., Eby, Y. et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11, 210–212 (1995).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing